Loading...
XNAS
IBIO
Market cap34mUSD
Apr 10, Last price  
2.16USD
1D
-1.82%
1Q
-20.00%
Jan 2017
-99.89%
IPO
-99.99%
Name

Ibio Inc

Chart & Performance

D1W1MN
XNAS:IBIO chart
P/E
—
P/S
151.58
EPS
—
Div Yield, %
—
Shrs. gr., 5y
151.79%
Rev. gr., 5y
-35.52%
Revenues
225k
896,273987,0581,176,6040520,0801,277,3451,007,000205,0001,851,000948,000394,000444,0002,018,0001,638,0002,371,0002,383,0000225,000
Net income
-25m
L-15.03%
-1,666,034-1,869,295-1,907,296-6,078,020-12,142,451-5,675,838-6,198,000-3,666,000-6,625,000-9,764,000-14,532,000-16,105,000-17,593,000-18,915,000-23,259,000-51,005,000-29,311,000-24,907,000
CFO
-19m
L-39.04%
-849,378-1,149,451-2,024,807-2,348,223-5,338,188-6,009,646-4,849,000-4,116,000-4,725,000-8,072,000-13,163,000-13,480,000-13,975,000-13,345,000-30,064,000-37,480,000-30,436,000-18,554,000
Earnings
Apr 30, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
URL
https://www.ibioinc.com/
IPO date
Aug 18, 2008
Employees
105
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT